ES2392391T3 - Método para modular la activación de macrófagos - Google Patents

Método para modular la activación de macrófagos Download PDF

Info

Publication number
ES2392391T3
ES2392391T3 ES99903869T ES99903869T ES2392391T3 ES 2392391 T3 ES2392391 T3 ES 2392391T3 ES 99903869 T ES99903869 T ES 99903869T ES 99903869 T ES99903869 T ES 99903869T ES 2392391 T3 ES2392391 T3 ES 2392391T3
Authority
ES
Spain
Prior art keywords
compound
use according
pharmaceutically acceptable
disease
neuronal cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99903869T
Other languages
English (en)
Spanish (es)
Inventor
Celine Morissette
Francine Gervais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BHI LP
Bellus Health International Ltd
Original Assignee
BHI LP
Bellus Health International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BHI LP, Bellus Health International Ltd filed Critical BHI LP
Application granted granted Critical
Publication of ES2392391T3 publication Critical patent/ES2392391T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ES99903869T 1998-02-11 1999-02-11 Método para modular la activación de macrófagos Expired - Lifetime ES2392391T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7429598P 1998-02-11 1998-02-11
US74295P 1998-02-11
US24839699A 1999-02-10 1999-02-10
US248396 1999-02-10
PCT/IB1999/000354 WO1999040909A1 (en) 1998-02-11 1999-02-11 Method for modulating macrophage activation

Publications (1)

Publication Number Publication Date
ES2392391T3 true ES2392391T3 (es) 2012-12-10

Family

ID=26755484

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99903869T Expired - Lifetime ES2392391T3 (es) 1998-02-11 1999-02-11 Método para modular la activación de macrófagos

Country Status (12)

Country Link
EP (1) EP1054664B1 (https=)
JP (1) JP4574845B2 (https=)
AU (1) AU2437899A (https=)
CA (2) CA2320224C (https=)
CY (1) CY1113205T1 (https=)
DK (1) DK1054664T3 (https=)
ES (1) ES2392391T3 (https=)
IL (1) IL137751A0 (https=)
MX (2) MX2008014823A (https=)
NZ (2) NZ568553A (https=)
PT (1) PT1054664E (https=)
WO (1) WO1999040909A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
WO1999059571A1 (en) * 1998-05-15 1999-11-25 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
US6310073B1 (en) 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
EP1237547A2 (en) * 1999-07-09 2002-09-11 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
EP1251837A2 (en) 1999-12-23 2002-10-30 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
AU2003292936A1 (en) * 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7253306B2 (en) 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
BRPI0411800A (pt) * 2003-06-23 2006-08-08 Neurochem Int Ltd candidatos a fármacos e métodos para sua preparação
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20120004160A1 (en) * 2009-02-19 2012-01-05 Glaxo Group Ltd. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
MX2012003212A (es) * 2009-09-17 2012-09-07 North Texas Medical Ass Papel del acido n-2-hidroxi-etil-piperazina-n´-2-etano sulfonico (hepes) en el control del dolor y reversion de lesiones por desmielinizacion.
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2016163886A2 (en) * 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
CN109381452A (zh) * 2017-08-11 2019-02-26 江西青峰药业有限公司 乙基硫酸类化合物的应用及其制备方法
CN109381453A (zh) * 2017-08-14 2019-02-26 江西青峰药业有限公司 乙基硫酸钾在制备用于预防或治疗炎症性疾病药物中的应用
CN109394746A (zh) * 2017-08-15 2019-03-01 江西青峰药业有限公司 乙基硫酸铵在制备用于预防或治疗炎症性疾病药物中的应用
US20250345298A1 (en) 2022-04-28 2025-11-13 Alzheon, Inc. Apoe4 correctors and methods of use
AU2023403257A1 (en) 2022-12-02 2025-06-12 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140049A (en) * 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
IL134619A0 (en) * 1997-08-18 2001-04-30 Univ Kingston Phosphono-carboxylate compounds for treating amyloidosis
US5869469A (en) * 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis

Also Published As

Publication number Publication date
NZ550199A (en) 2008-07-31
EP1054664B1 (en) 2012-08-08
CA2632106A1 (en) 1999-08-19
PT1054664E (pt) 2012-11-02
DK1054664T3 (da) 2012-11-05
WO1999040909A1 (en) 1999-08-19
CY1113205T1 (el) 2016-04-13
JP2002502871A (ja) 2002-01-29
CA2320224A1 (en) 1999-08-19
EP1054664A1 (en) 2000-11-29
JP4574845B2 (ja) 2010-11-04
IL137751A0 (en) 2001-10-31
AU2437899A (en) 1999-08-30
HK1032915A1 (en) 2001-08-10
MX2008014823A (es) 2009-03-06
CA2320224C (en) 2008-08-12
NZ568553A (en) 2010-02-26
MXPA00007815A (es) 2002-04-24

Similar Documents

Publication Publication Date Title
ES2392391T3 (es) Método para modular la activación de macrófagos
ES2283071T3 (es) Modulacion de la carga de medicamenteos en liposomas multivesiculares.
US11357724B2 (en) Pharmaceutical composition, preparation and uses thereof
RU2215522C2 (ru) Способ эпидурального введения терапевтических соединений с поддерживаемой скоростью высвобождения, способ уменьшения угнетения дыхания
Kreuter Liposomes and nanoparticles as vehicles for antibiotics
KR102666251B1 (ko) 약학적 조성물, 이의 제조 및 용도
CA2296056A1 (en) Methods for universally distributing therapeutic agents to the brain
EP1496860A1 (en) Localized non-invasive biological modulation system
ES2951598T3 (es) Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos
TW201628639A (zh) 醫藥組合物、其製備及其用途
Bagmar et al. A review on targeted drug delivery system
US8753673B2 (en) Liposome composition for delivery of a therapeutic agent to eyes
Hwang Targeted delivery of erythropoietin hybridized with magnetic nanocarriers for the treatment of central nervous system injury: A literature review
Derman et al. Brain-Targeted Nano-Drug Delivery for the Treatment of Parkinson's Disease
Swain et al. Current Approaches to Smart Drug Delivery
HK1032915B (en) Method for modulating macrophage activation
WO2011036619A2 (en) Two step ultrasound protocol for drug delivery
AbouElhassan et al. Prospective role of Citicoline and nanotechnology as drug delivery approaches for Alzheimer’s disease: Review of the literature
Sharma et al. Preparation and Evaluation of Gliptin Liposomes for Targetting Ocular Region in Neurodegeneration
Elzwi Genesis Journal of Surgery and Medicine
Paudel et al. Recent advancement in drug delivery system
Malyshok et al. LIPOSOMES IN HUMAN THERAPY: A REVOLUTION IN DRUG DELIVERY
EP4132469A1 (en) Administration of mtor inhibitors into the central nervous system
AU2002362611A1 (en) Localized non-invasive biological modulation system